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Abstract Resistance of bacteria to antimicrobial agents is
a worldwide concern. In Korea, resistant bacteria are
more prevalent than in other industrialized countries.
Methicillin-resistant Staphylococcus aureus, erythromycin-
resistant Streptococcus pyogenes, penicillin non-susceptible
pneumococci, -lactamase-producing gonococci, extended-
spectrum -lactamase (ESBL)-producing Escherichia coli
and Klebsiella pneumoniae, class C -lactamase-producing
E. coli, ﬂuoroquinolone-resistant E. coli, and aminoglyco-
side-resistant Acinetobacter baumannii and Pseudomonas
aeruginosa are examples of resistant bacteria prevalent in
Korea, and their presence suggests a high level of anti-
microbial selective pressure and the nosocomial spread of
resistant bacteria. Recently observed rapid increases in the
incidence of vancomycin-resistant Enterococcus faecium
and carbapenem-resistant P. aeruginosa present new threats
in Korea.
Key words Antimicrobial resistance in Korea · Resistance
survey · Nosocomial pathogen
Introduction
It was in the early 1990s that prominent scientists viewed
resistance to antimicrobial agents as a crisis and calamity.1,2
They insisted that the extensive use of antibiotics in the
community and hospitals fueled the crisis in antibiotic resis-
tance, which resulted in virtually all pathogenic bacteria
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becoming resistant to older antibiotics. During the past sev-
eral years, the antibiotic resistance problem has worsened
noticeably in Korea. The increased prevalence of known
resistant organisms and the emergence of newly resistant,
organisms such as vancomycin-resistant enterococci
(VRE), extended-spectrum -lactamase (ESBL)-producing
Escherichia coli and Klebsiella pneumoniae, imipenem-
resistant Pseudomonas aeruginosa, and ﬂuoroquinolone-
resistant gram-negative bacilli, have become of real
concern.
The methods used to test antimicrobial susceptibility
used may affect the result. In Korea, the majority of
laboratories use the disk diffusion method, although some
large hospitals use the commercial broth microdilution test.
The disk diffusion method used is the only National Com-
mittee for Clinical Laboratory Standards (NCCLS) ap-
proved method, except for some antimicrobial agents for
which NCCLS breakpoints are not available.3 Most reports
on antimicrobial resistance in Korea were based on isolates
in large tertiary care hospitals. Therefore, the resistance
rates were inﬂuenced by the prevalence of nosocomial in-
fections. The analysis of resistance of isolates from outpa-
tients may also fail to show true resistance rates of
community-acquired pathogens, as some of the outpatients
may have acquired the organisms in hospitals.
Before presenting the current resistance status of some
of the more important pathogens, we brieﬂy present the
trend of resistance in the recent past in a tertiary care
hospital, together with the resistance pattern of Neisseria
gonorrhoeae from other studies, to show the general picture
of resistance in Korea (Figs. 1, 2). Trends show that
methicillin-resistant Staphylococcus aureus (MRSA),
penicillin-resistant Streptococcus pneumoniae, ampicillin-
resistant Haemophilus inﬂuenzae, and piperacillin-resistant
Pseudomonas aeruginosa were already prevalent in the
early 1990s, and all of their resistance rates were over 50%
in 1999. During this period, VRE, ESBL-producing K.
pneumoniae, cefoxitin-resistant E. coli, imipenem-resistant
P. aeruginosa, and ﬂuoroquinolone-resistant E. coli
have emerged and their resistance rates have increased
signiﬁcantly.
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Resistance of staphylococci
S. aureus is an important pathogen, frequently isolated from
both outpatients and inpatients with various infections.
The increased prevalence of MRSA, a typical nosocomial
pathogen, is a serious problem, because it is resistant to all
existing -lactam antibiotics. In Korea, MRSA was not de-
tected in the 1960s. During the period 1971–1979, 3% to 9%
of S. aureus isolates from blood were methicillin-
resistant, but in 1980 the rate was 25%.4 In the same hospital,
the methicillin-resistance rates of all S. aureus rose sharply,
to 44%, in 1988 and gradually rose again to reach around
70% in 1995. In a 1998 Korean survey, the methicillin resis-
tance rate was found to be 72% (Table 1).5 In a study of
strains from wounds, those isolated in the 1990s were found
to be highly resistant, with a methicillin minimum inhibitory
concentration for 50% of isolates (MIC50) of 512 μg/ml. It
was also noted that the prevalence of coagulase type II
increased to 30% and that most were expression class 3 or 4.6
In Korea, arbekacin is not used, and a 1996 study showed that
all of the isolates tested were susceptible to this drug.7
The emergence of a vancomycin-resistant (intermediate)
S. aureus (VISA) in 1996 in Japan, caused new concerns.
Studies were undertaken to search for VISA in several
Korean hospitals. Kim et al.8 identiﬁed a VISA isolate
among MRSAs isolated from a pelvic abscess specimen of a
45-year-old man. However, other workers were not able to
Fig. 1. Trends in antimicrobial resistance of gram-positive and gram-
negative cocci between 1988 and 1999 in a tertiary care hospital in
Korea. The resistance rates of Neisseria gonorrhoeae are cited from
other studies. MRSA, Methicillin-resistant Staphylococcus aureus;
PEN-NSSPN, penicillin-nonsusceptible Streptococcus pneumoniae;
AMP-R EFM, ampicillin-resistant Enterooccus faecium; VAN-R EFM,
vancomycin-resistant E. faecium; PPNG, penicillinase-producing
Neisseria gonorrhoeae
Fig. 2. Trends in antimicrobial resistance of gram-negative bacilli be-
tween 1988 and 1999 in a tertiary care hospital in Korea. FQN-R ECO,
Fluoroquinolone-resistant Escherichia coli; FOX-R ECO, cefoxitin-
resistant E. coli; CTX-R KPN, cefotaxime-resistant Klebsiella
pneumoniae; CAZ-R PAE, ceftazidime-resistant Pseudomonas
aeruginosa; IMP-R PAE, imipenem-resistant P. aeruginosa
Table 1. Antimicrobial resistance rates of important aerobic gram-positive cocci isolated in 1998
in Korea
Species (no. tested)a Antimicrobial agents Resistance rate (%)
Staphylococcus aureus (26 042) Oxacillin 72
Clindamycin 63
Fluoroquinolone 66
Cotrimoxazole 3
Streptococcus pyogenes (41) Erythromycin 27
S. agalactiae (40) Erythromycin 26
S. pneumoniae (2187) Penicillin non-susceptible 78
Enterococcus faecium (2968) Ampicillin 80
Vancomycin 11
E. faecalis (7075) Vancomycin 0.6
a Cited from references 5 and 9; S. pyogenes and S. agalactiae were isolated in the period
1993–1996
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detect any VISA isolates. We screened for the presence of
Mu3 type strains, using Mu3 agar, and found that 15% of
the isolates showed satellitism around the aztreonam disk.
Population analysis demonstrated that they were not VISA
strains, but contained subpopulations which were resistant
to vancomycin, indicating their potential to become VISA.
Resistance of streptococci and enterococci
In Korea, Streptococcus pyogenes remained very sus-
ceptible to -lactam antibiotics, i.e., the MIC of penicillin G
was 0.015 μg/ml, while the resistance rate to erythromycin
was 27% (Table 1) and to that tetracycline was 56%.9 The
resistance rates to these drugs in Korea were much higher
than the 2.7% and 16.5% found in Japan during the early
1990s.10
S. agalactiae neonatal infection is much less frequent in
Korea than in the United States, probably because of the
lower genital carriage rate, 5.9%, in Korean pregnant
women.11 The prevalent serotypes remain Ia, Ib, and III,
while new serotypes, VI and VIII, have been detected
recently.9 S. agalactiae is between ﬁve-fold and eight-fold
less susceptible to penicillin than S. pyogenes. In our study,
the MIC range of penicillin G for S. agalactiae was 0.03–
0.06μg/ml.9 The resistance rate to erythromycin was 26%
(Table 1) and that to tetracycline was 100%, rates which
were much higher than those in Japan in 1986–1992 (i.e.,
1.2% and 42%, respectively).10
S. pneumoniae is an important pathogen that causes a
variety of infections, some of which are serious. The
increase in penicillin G-non-susceptible pneumococci has
become a serious problem in many parts of the world.12 The
penicillin non-susceptible rate in a Korean tertiary care
hospital rose from 3% in 1986 to 29% in 1988, and then
increased to 77% in 1993.13 Similar results have been
reported in other hospitals.14,15 Capsular types 19F and 23F
were frequently isolated, and these types of isolates were
often non-susceptible to penicillin G. A Korean nationwide
survey in 1998 showed the mean penicillin non-susceptible
rate to be 78% (Table 1), which was much higher than the
52% reported in Japan during 1994–1995.16
Enterococci became more frequently isolated from
inpatients, and the proportion of Enterococcus faecium
increased to 38% of all enterococci in Korean tertiary
hospitals. The ampicillin-resistance rate of E. faecalis is very
low, but the ampicillin-resistance rate of E. faecium was
80% in 1998 (Table 1), and 96% in 1999 in a tertiary care
hospital (Fig. 1). Although most enterococci were isolated
from urine specimens, some were isolated from blood
specimens. As enterococci are inherently less susceptible to
-lactam antibiotics, enterococcal endocarditis is treated
with aminoglycoside combinations. However, a gradual
increase in high-level aminoglycoside-resistant isolates has
been noted. In a Korean tertiary care hospital in the period
1991–1992, high-level resistance rates to gentamicin were
20% in E. faecalis and 59% in E. faecium.17 In another
study, the resistance rates to gentamicin and streptomycin
were: E. faecalis, 61% and 39%, respectively; and E.
faecium, 45% and 55%, respectively.18
The ﬁrst isolation of VRE in Korea was reported in
1992,19 but it was rare. In a tertiary care hospital, among the
31 E. faecalis and 11 E. faecium strains isolated from blood
during the period 1996–1998, only one isolate of E. faecium
was resistant to vancomycin.18 However, in another tertiary
care hospital, the proportion of vancomycin-resistant E.
faecium started to rise sharply in 1998 (Fig. 1) and reached
29% in 1999. Most of the VRE were E. faecium of type
VanA. Pulsed-ﬁeld gel electrophoresis (PFGE) patterns
suggested that both the clonal and the horizontal spread of
resistance were the cause of the sharp increase. Donskey et
al.20 noted that it was difﬁcult to control the spread of VRE
by infection control measures alone.
Resistance of Neisseria and Moraxella
Low-level penicillin G-resistant isolates of N. gonorrhoeae
were already prevalent in Korea in the 1960s, but a
penicillinase-producing strain (PPNG) was ﬁrst reported in
1979. In the 1990s, almost all isolates were resistant to
penicillin G, either by chromosomal resistance or by -
lactamase production (Table 2). Since the early 1990s, the
proportion of PPNG has been to over 70% (Fig. 1).21,22
However, the isolates remained highly susceptible to
ceftriaxone, i.e., the MIC range was 0.008–0.06μg/ml. A
recent decrease in PPNG in other countries is probably
related to the increase in quinolone-resistant strains, as re-
ported in Hong Kong.23 In Japan, the ciproﬂoxacin resis-
tance rate of gonococci isolated in the period 1997–1998 was
Table 2. Antimicrobial susceptibility of gonococci isolated in 1997–1999 in Korea
Antimicrobial Strains MIC range Percentage of isolates
agents (no. tested ) (μg/ml)
Susceptible Intermediate Resistant
Penicillin G Non-PPNG (29) 0.12–1 0 100 0
PPNG (144) 2–128 0 0 100
Ciproﬂoxacin Non-PPNG (29) 0.008–0.5 59 41 0
PPNG (144) 0.008–1 35 64 1
Tetracycline All (173) 1–8 0 13 87
MIC, Minimum inhibitory concentration; PPNG, penicillinase-producing Neissseria gonorrhoeae
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23.6%,24 while the ciproﬂoxacin resistance rate of PPNG
was only 4% in 1994.25 In Korea, isolates of gonococci often
showed intermediate resistance to ciproﬂoxacin (i.e., MICs
were 1μg/ml) until 1999, but high-level resistant isolates
started to be isolated in 2000. Spectinomycin-resistant
gonococci remained rare, as was reported in other Asian
countries.25 Moraxella (Branhamella) catarrhalis is not fre-
quently isolated from clinical specimens in Korea. Studies
showed that approximately 95% of recent isolates were
producing -lactamase.
Resistance of gram-negative bacilli to -lactams
Enterobacteriaceae and glucose-nonfermenting gram-
negative bacilli are frequently isolated from various
community-acquired and nosocomial infections. Some of
the current resistance problems with Enterobacteriaceae
are an increase in the numbers of ESBL- or AmpC -
lactamase-producing strains of E. coli and K. pneumoniae,
and increases in AmpC -lactamase-hyperproducing strains
of Enterobacter, Citrobacter, and Serratia spp. In a
Korean  survey in 1998, which involved 25 hospitals, resis-
tance rates of E. coli were 78% to ampicillin and
 44% to cephalothin (Table 3). Cefotaxime resistance rates,
determined by regular NCCLS breakpoint, were 8% for
E. coli and 22% for K. pneumoniae. Therefore, ESBL-
producing strains must be more prevalent than what is
shown by the above rates. In a hospital, the rates of
cefotaxime-susceptible E. coli and K. pneumoniae de-
creased from 99% to 89% and from 94% to 70%, respec-
tively, during the period 1986 to 1993.26 Among the
non-susceptible isolates, 69% of E. coli and 76% of K.
pneumoniae were double-disk synergy-positive, indicating
that they were ESBL producers. It was reported that ESBL-
producing E. coli and K. pneumoniae were isolated only
from nosocomially infected patients, which indicated
that they were nosocomial pathogens.27 In a tertiary care
hospital in 1999, resistance rates of isolates from inpatients
and outpatients were: E. coli for cefotaxime, 23.6% vs 2.5%;
and ceftazidime, 7.9% vs 1.7%; K. pneumoniae for cefo-
taxime, 17.5% vs 2.3%; and ceftazidime, 31.7% vs 3.6%.
These ﬁndings suggest that the nosocomial spread of ESBL-
producing strains is a signiﬁcant cause of their high
prevalence.
It was reported that, of ﬁve ESBL-producing isolates,
four produced TEM-type and 1 produced SHV-type en-
zymes.28 Pai et al.29 reported that the most prevalent
ESBL types of K. pneumoniae, isolated at three university
hospitals, were SHV-2, and SHV-12a, and TEM-52 types
were reported later. It is interesting that Toho- and
Kitasato-type ESBLs, found in Japan, have not yet been
detected in Korea.
Since 1989, over 15 plasmid-encoded AmpC -
lactamases have been reported worldwide.30 A class C -
lactamase, CMY-1, was ﬁrst identiﬁed from K. pneumoniae
in Korea in 1988. Bauernfeind et al.31 reported that CMY-
1b had an amino acid change from Asn at position 346
of CMY-1a to Ile, resulting in increased resistance to
ceftazidime. A survey in 1998 showed that 12% of E. coli
and 14% of K. pneumoniae were resistant to cefoxitin.5 Pai
et al.29 reported that AmpC -lactamase was detected in 8 of
57 K. pneumoniae isolates. Among the cefoxitin-resistant E.
coli and K. pneumoniae, 6 of 19 and 3 of 7, respectively, had
the conjugatively transferable CMY-1 -lactamase gene. 32
Enterobacter, Citrobacter, and Serratia spp. frequently
cause nosocomial infections and are often resistant to third
generation cephalosporins. In the 1998 survey, in Korea
47% and 51% of E. cloacae and S. marcescens, respectively,
were resistant to cefotaxime (Table 3);5 resistance rates to
ceftazidime were 48% and 25%, respectively. Cefepime is
Table 3. Antimicrobial resistance rates of Enterobacteriaceae and glucose-nonfermenting gram-negative bacilli isolated in 1998 in Korea
Antimicrobial agents Percentage of isolates resistant (no. tested)a
E. coli K. pneumoniae E. cloacae S. marcescens A. baumannii P. aeruginosa
(20,604) (9079) (5781)  (3324) (11866) (20370)
Ampicillin 78 NT NT NT NT NT
Aminopenicillin/sulbactam 29 25 67 93 14 NT
 or clavulanic acid
Piperacillin 61 35 54 38 75 43
Piperacillin/tazobactam 5 10 35 37 43 35
Cephalothin 44 38 NT NT NT NT
Cefotaxime 8 22 47 51 83 NT
Ceftazidime 7 25 48 25 64 17
Cefoxitin 12 14 97 74 98 NT
Cefotetan 5 4 57 9 82 NT
Imipenem 0 0 0.8 1 5 17
Amikacin 5 9 16 20 60 30
Gentamicin 32 28 47 48 79 50
Tobramycin 25 32 51 62 78 48
Fluoroquinolonea 25 8 16 22 71 42
NT, Not tested
a Tested either by ciproﬂoxacin, levoﬂoxacin, or oﬂoxacin
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active against class C -lactamase-producing isolates. In
1991, it was reported that all isolates of Enterobacteriaceae
tested were susceptible to cefepime,33 and in 2000 in a ter-
tiary care hospital, cefepime-resistant isolates remained
rare, i.e., 1% each for E. coli and E. cloacae and 2% for K.
pneumoniae and 4% for S. marcescens; none of the other
species of Enterobacteriaceae were resistant.
Imipenem is the most active -lactam drug against
gram-negative bacilli, including P. aeruginosa and
Acinetobacter baumannii. Imipenem-resistant P. aeruginosa
and other gram-negative bacilli with IMP-1 -lactamase-
production were reported in Japan.34 This report was fol-
lowed by others of carbapenemase-producing P. aeruginosa
and A. baumannii in Italy, Greece, and France.35 In a
Korean hospital, the imipenem-resistance rates of
P. aeruginosa were 3% to 6% during the period 1994–
1996, but in the period 1997–1999, the rates rose to 14%–
15%. This tendency was also observed in other Korean
hospitals. Some of this resistance was due to a decrease of
outer membrane protein, but 8.7% of the imipenem-
resistant isolates produced carbapenemase.36 Interestingly,
the polymerase chain reaction showed that the carba-
penemase was not an IMP-type, but a VIM-type -
lactamase. It is of great concern that carbapenem resistance
in Korea is increasing and that it is transferable by
conjugation.
Resistance of gram-negative bacilli to
ﬂuoroquinolones and aminoglycosides
Ciproﬂoxacin, oﬂoxacin, and levoﬂoxacin are ﬂuoro-
quinolones that are very active against gram-negative
bacilli, including enteric pathogens; however, increasing
resistance is a worldwide concern.37 In a Korean hospital,
only 5% of E. coli and 1% of K. pneumoniae were resistant
to oﬂoxacin in 1991, but these rates rose rapidly, to 26% and
19%, respectively, in 1994. The resistance rate of E. coli to
the ﬂuoroquinolone was 33% in 1999 (Fig. 2). The 1998
survey showed that resistance to the agent was more
prevalent in large hospitals (deﬁned as those with 1000 or
more beds) compared with other hospital size categories),
particularly in E. coli (Table 4).5 In a tertiary care hospital in
1999, the ﬂuoroquinolone resistance rates of isolates from
inpatients and outpatients were: E. coli, 39.8% vs 19.4%; K.
pneumoniae, 13.8% vs 1.6%. These results suggest the pres-
ence of nosocomial infections with ﬂuoroquinolone-resis-
tant E. coli and K. pneumoniae, together with existence of
ﬂuoroquinolone-resistant E. coli in the community. The
ﬂuoroquinolone resistance rates of P. aeruginosa and
A. baumannii in the 1998 survey were 24% to 39% and 23%
to 58%, respectively, depending on the hospital size
category.
The aminoglycoside-resistance pattern in the Far East
was reported to differ from that in the United States.38 In
1998, the amikacin resistance rates of E. coli and K.
pneumoniae in Korea were relatively low, at 5% and 9%,
respectively (Table 3), but the rates for E. cloacae and S.
marcescens were 16% and 20%, respectively, and rates were
much higher for A. baumannii and P. aeruginosa, at 60%
and 30%, respectively. Gentamicin resistance rates were
32% for E. coli, 28% for K. pneumoniae, 48% for S. marces-
cens, 79% for A. baumannii, and 50% for P. aeruginosa.
Tobramycin resistance rates were similar to those for
gentamicin.
Resistance of Salmonella and Shigella
Ampicillin-resistant non-typhoidal Salmonella was rare in
Korea until the early 1980s, i.e., only 4 of 211 isolates were
resistant during the period 1979–1983. In 1986, 65% or
more of Salmonella serovar Typhimurium were resistant to
ampicillin, chloramphenicol, or tetracycline.39 In another
study, 36% of Salmonella Typhimurium were resistant to
ampicillin,40 and this rate was similar to that in Japan.41
During the period 1995–1997, 5 strains of nontyphoidal
Salmonella were isolated which produced TEM-52 ESBL.
Typhoid fever was prevalent until the early 1980s
in Korea, but, since the early 1980s, the isolation of
Salmonella Typhi has rapidly decreased and non-typhoidal
Salmonella has increased. Antibiotic-resistant Salmonella
Typhi was not known to exist until an isolate was detected
in 1992 from a patient who had traveled to South East
Asian countries. Two resistant isolates were again isolated
at the same hospital in 1995. In 1997, 11% and 15% of the
isolates collected by the National Institute of Health
Korea were resistant to ampicillin and chloramphenicol,
respectively.40
Bacillary dysentery was very prevalent in the past, but
now it occurs much less frequently. It was reported that,
among the Shigella strains isolated in 1998, 8% were S.
ﬂexneri and 92% were S. sonnei.42 S. ﬂexneri is well known
for its antimicrobial resistance. Among the S. sonnei isolates
in 1998, 99% were resistant to cotrimoxazole and 71% were
resistant to ampicillin.
Resistance of Haemophilus inﬂuenzae to -lactams
H. inﬂuenzae is a frequent causative agent of bacterial men-
ingitis. In the early 1980s, 9% of H. inﬂuenzae isolates in
Korea were resistant to ampicillin, by -lactamase produc-
tion.43 The rate gradually rose, and in the 1998 survey, it was
56%,5 a rate that was much higher than that reported in the
United States (34% in 1993–199744) and that reported in
Japan (13.3% in 1996–199845). In the 1998 survey, -
lactamase-positivity rates of H. inﬂuenzae were similar
in large and medium (less than 1000 beds) hospitals
(Table 4). -Lactamase-negative ampicillin-resistant
(BLNAR) strains and -lactamase-positive aminopenicillin/
clavulanate-resistant (BLPACR) strains exist in Japan, but
such strains have not been studied in Korea, as yet.
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Resistance of Bacteroides fragilis
Among the anaerobic bacteria, the Bacteroides species
often cause infections. Only 1% of B. fragilis isolated in
Korea in the period 1995–1996 showed resistance to
cefoxitin, but the clindamycin resistance rate was 43%, a
rate much higher than that in other countries.46 During the
period 1989–1996, none of the isolates of B. fragilis were
resistant to imipenem, metronidazole, or chloramphenicol,
but the resistance rates to piperacillin and cefotaxime dur-
ing this period rose markedly, from 12% to 25%, and from
17% to 33%, respectively. In general, the resistance rates of
the non-fragilis B. fragilis group species were higher than
those of B. fragilis.
In summary, methicillin-resistant S. aureus,
erythromycin-resistant S. pyogenes, penicillin non-
susceptible pneumococci, -lactamase-producing gono-
cocci, ESBL-producing E. coli and K. pneumoniae, class C
-lactamase-producing E. coli, ﬂuoroquinolone-resistant
E. coli, and aminoglycoside-resistant A. baumannii and
P. aeruginosa are more prevalent in Korea, at higher rates
than in other countries; this suggests the presence of high
levels of antimicrobial selective pressure and the noso-
comial spread of resistant bacteria. The recently observed
rapid increases in vancomycin-resistant E. faecium and
carbapenem-resistant P. aeruginosa present new threats in
Korea.
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